Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors
NCT01413906
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
BMS-833923 (XL139)
Sponsor
Bristol-Myers Squibb